The University of Chicago Header Logo

Connection

Michael H. Davidson to Risk Factors

Back to Details
This is a "connection" page, showing publications Michael H. Davidson has written about Risk Factors.
Michael H. Davidson
Connection Strength
3.511
Risk Factors
  1. Recent advances and emerging therapies in management of dyslipidemias. Trends Cardiovasc Med. 2021 10; 31(7):419-424.
    View in: PubMed
    Score: 0.090
  2. Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials. Eur J Cancer. 2019 11; 121:40-47.
    View in: PubMed
    Score: 0.084
  3. The Role of Genetics in Cardiovascular Risk Reduction: Findings From a Single Lipid Clinic and Review of the Literature. Cardiovasc Revasc Med. 2020 02; 21(2):200-204.
    View in: PubMed
    Score: 0.082
  4. Cardiorenal Safety of OTC Analgesics. J Cardiovasc Pharmacol Ther. 2018 03; 23(2):103-118.
    View in: PubMed
    Score: 0.076
  5. Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia. Vasc Health Risk Manag. 2016; 12:481-490.
    View in: PubMed
    Score: 0.070
  6. Using Discordance in Monozygotic Twins to Understand Causality of Cardiovascular Disease Risk Factors. JAMA Intern Med. 2016 10 01; 176(10):1530.
    View in: PubMed
    Score: 0.069
  7. The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter? Prog Cardiovasc Dis. 2016 Sep - Oct; 59(2):145-152.
    View in: PubMed
    Score: 0.068
  8. Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. Curr Atheroscler Rep. 2015 Dec; 17(12):72.
    View in: PubMed
    Score: 0.065
  9. Changing characteristics of statin-related cIMT trials from 1988 to 2006. Atherosclerosis. 2016 Mar; 246:121-9.
    View in: PubMed
    Score: 0.065
  10. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. Postgrad Med. 2014 May; 126(3):56-65.
    View in: PubMed
    Score: 0.058
  11. Overcoming toxicity and side-effects of lipid-lowering therapies. Best Pract Res Clin Endocrinol Metab. 2014 Jun; 28(3):439-52.
    View in: PubMed
    Score: 0.057
  12. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013 Dec 10; 62(23):2178-84.
    View in: PubMed
    Score: 0.056
  13. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013 Sep; 35(9):1400-11.e1-3.
    View in: PubMed
    Score: 0.056
  14. Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist. Am J Cardiol. 2012 Nov 06; 110(9 Suppl):43B-49B.
    View in: PubMed
    Score: 0.052
  15. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
    View in: PubMed
    Score: 0.052
  16. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol. 2013 Mar-Apr; 7(2):102-8.
    View in: PubMed
    Score: 0.051
  17. The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk. Curr Atheroscler Rep. 2011 Oct; 13(5):373-80.
    View in: PubMed
    Score: 0.049
  18. Pharmacotherapy: Implications of high-dose statin link with incident diabetes. Nat Rev Cardiol. 2011 Aug 02; 8(10):543-4.
    View in: PubMed
    Score: 0.048
  19. Focusing on high-density lipoprotein for coronary heart disease risk reduction. Cardiol Clin. 2011 Feb; 29(1):105-22.
    View in: PubMed
    Score: 0.046
  20. CNS infection in childhood does not confer risk for later schizophrenia: a case-control study. Schizophr Res. 2010 Dec; 124(1-3):231-5.
    View in: PubMed
    Score: 0.045
  21. Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study. Arterioscler Thromb Vasc Biol. 2010 Sep; 30(9):1873-6.
    View in: PubMed
    Score: 0.045
  22. Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence. J Clin Lipidol. 2010 Jan-Feb; 4(1):72-3; discussion 74.
    View in: PubMed
    Score: 0.043
  23. Lp-PLA2: A new target for statin therapy. Curr Atheroscler Rep. 2010 Jan; 12(1):29-33.
    View in: PubMed
    Score: 0.043
  24. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009 Dec; 31(12):2824-38.
    View in: PubMed
    Score: 0.043
  25. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol. 2009 Sep; 32(9):482-6.
    View in: PubMed
    Score: 0.042
  26. A review of lipid management in primary and secondary prevention. J Cardiopulm Rehabil Prev. 2009 Jan-Feb; 29(1):2-12.
    View in: PubMed
    Score: 0.040
  27. Updating the assessment of cardiac risk: beyond Framingham. Rev Cardiovasc Med. 2009; 10(2):63-71.
    View in: PubMed
    Score: 0.040
  28. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol. 2008 Dec 22; 102(12A):19L-27L.
    View in: PubMed
    Score: 0.040
  29. Should every patient with diabetes receive a statin? Pol Arch Med Wewn. 2008 Jul-Aug; 118(7-8):398-401.
    View in: PubMed
    Score: 0.039
  30. Introduction. U.S. incidence of coronary artery disease. Am J Cardiol. 2008 Jun 16; 101(12A):1F-2F.
    View in: PubMed
    Score: 0.039
  31. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008 Jun 16; 101(12A):41F-50F.
    View in: PubMed
    Score: 0.039
  32. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008 Jun 16; 101(12A):51F-57F.
    View in: PubMed
    Score: 0.039
  33. High-dose statin therapy: benefits and safety in aggressive lipid lowering. J Fam Pract. 2008 May; 57(5 Suppl High-Dose):S29-36.
    View in: PubMed
    Score: 0.038
  34. Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am J Cardiol. 2008 Apr 17; 101(8A):14B-19B.
    View in: PubMed
    Score: 0.038
  35. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol. 2008 Apr 17; 101(8A):27B-35B.
    View in: PubMed
    Score: 0.038
  36. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation. 2008 Apr 22; 117(16):2123-30.
    View in: PubMed
    Score: 0.038
  37. Usefulness of increased skin cholesterol to identify individuals at increased cardiovascular risk (from the Predictor of Advanced Subclinical Atherosclerosis study). Am J Cardiol. 2008 Apr 01; 101(7):986-91.
    View in: PubMed
    Score: 0.038
  38. Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. Am J Manag Care. 2007 Dec; 13 Suppl 10:S260-9.
    View in: PubMed
    Score: 0.037
  39. Effectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data. Int J Clin Pract. 2007 Oct; 61(10):1634-42.
    View in: PubMed
    Score: 0.037
  40. Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals. Curr Med Res Opin. 2007 May; 23(5):1121-30.
    View in: PubMed
    Score: 0.036
  41. Socioeconomic status in relationship to death of vascular disease and late-life dementia. J Neurol Sci. 2007 Jun 15; 257(1-2):177-81.
    View in: PubMed
    Score: 0.036
  42. Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults. Am J Clin Nutr. 2007 Mar; 85(3):724-34.
    View in: PubMed
    Score: 0.035
  43. Reducing the risk of stroke through appropriate targets and treatments. Prev Cardiol. 2007; 10(4):215-21.
    View in: PubMed
    Score: 0.035
  44. Global risk management in patients with type 2 diabetes mellitus. Am J Cardiol. 2007 Feb 19; 99(4A):41B-50B.
    View in: PubMed
    Score: 0.035
  45. Plasminogen activator inhibitor-1 and the risk of Type 2 diabetes mellitus in American Indians: the Strong Heart Study. Diabet Med. 2006 Oct; 23(10):1158-9.
    View in: PubMed
    Score: 0.034
  46. How low to target LDL? Nat Clin Pract Endocrinol Metab. 2006 Aug; 2(8):414-5.
    View in: PubMed
    Score: 0.034
  47. Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based study. Schizophr Res. 2006 Jul; 85(1-3):49-57.
    View in: PubMed
    Score: 0.033
  48. Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders. J Clin Exp Neuropsychol. 2006 Feb; 28(2):193-207.
    View in: PubMed
    Score: 0.033
  49. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006 Jan; 5(1):145-56.
    View in: PubMed
    Score: 0.033
  50. Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). J Cardiometab Syndr. 2006; 1(5):295-300.
    View in: PubMed
    Score: 0.033
  51. Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. Arch Gen Psychiatry. 2005 Dec; 62(12):1297-304.
    View in: PubMed
    Score: 0.032
  52. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol. 2005 Nov 07; 96(9A):44K-49K; discussion 34K-35K.
    View in: PubMed
    Score: 0.032
  53. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. Am J Cardiol. 2005 Nov 07; 96(9A):59K-64K; discussion 34K-35K.
    View in: PubMed
    Score: 0.032
  54. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol. 2005 Nov 07; 96(9A):3K-13K; discussion 34K-35K.
    View in: PubMed
    Score: 0.032
  55. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005 Aug 15; 96(4):556-63.
    View in: PubMed
    Score: 0.032
  56. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004 Nov 23; 63(10):1902-7.
    View in: PubMed
    Score: 0.030
  57. Reducing cardiovascular risk: trends in risk, risk assessment, and cholesterol management. Postgrad Med. 2004 Sep; 116(3 Suppl):7-12.
    View in: PubMed
    Score: 0.030
  58. Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am J Psychiatry. 2004 Jul; 161(7):1219-23.
    View in: PubMed
    Score: 0.029
  59. A look to the future: new treatment guidelines and a perspective on statins. Am J Med. 2002 Jun 03; 112 Suppl 8A:34S-41S.
    View in: PubMed
    Score: 0.025
  60. Use of filgrastim as adjuvant therapy in patients with AIDS-related cytomegalovirus retinitis. AIDS. 2002 Mar 29; 16(5):757-65.
    View in: PubMed
    Score: 0.025
  61. Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance. Am J Cardiol. 2002 Mar 07; 89(5A):8C-20C; discussion 20C-22C.
    View in: PubMed
    Score: 0.025
  62. Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry. 2002; 63 Suppl 9:5-11.
    View in: PubMed
    Score: 0.025
  63. Association between nonpsychotic psychiatric diagnoses in adolescent males and subsequent onset of schizophrenia. Arch Gen Psychiatry. 2001 Oct; 58(10):959-64.
    View in: PubMed
    Score: 0.024
  64. Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions. J Cardiovasc Pharmacol Ther. 2001 Jul; 6(3):219-29.
    View in: PubMed
    Score: 0.024
  65. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med. 2000 Nov 27; 160(21):3315-25.
    View in: PubMed
    Score: 0.023
  66. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct; 26(10):1196-1224.
    View in: PubMed
    Score: 0.023
  67. Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis. Curr Atheroscler Rep. 2020 07 25; 22(9):48.
    View in: PubMed
    Score: 0.022
  68. Does differing metabolism by cytochrome p450 have clinical importance? Curr Atheroscler Rep. 2000 Jan; 2(1):14-9.
    View in: PubMed
    Score: 0.022
  69. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 09; 288:85-93.
    View in: PubMed
    Score: 0.021
  70. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis. 2019 09; 288:194-202.
    View in: PubMed
    Score: 0.021
  71. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999 Jan 20; 281(3):235-42.
    View in: PubMed
    Score: 0.020
  72. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol. 2018 Oct; 41(10):1281-1288.
    View in: PubMed
    Score: 0.020
  73. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation. 1998 Aug 18; 98(7):628-33.
    View in: PubMed
    Score: 0.020
  74. Analysis of shared heritability in common disorders of the brain. Science. 2018 06 22; 360(6395).
    View in: PubMed
    Score: 0.019
  75. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. J Clin Lipidol. 2016 Nov - Dec; 10(6):1442-1451.e4.
    View in: PubMed
    Score: 0.017
  76. Risk of completed suicide in 89,049 young males assessed by a mental health professional. Eur Neuropsychopharmacol. 2016 Feb; 26(2):341-349.
    View in: PubMed
    Score: 0.016
  77. Carotid adventitial vasa vasorum and intima-media thickness in a primary prevention population. Echocardiography. 2015 Feb; 32(2):264-70.
    View in: PubMed
    Score: 0.015
  78. The prevalence of cervical infection with human papillomaviruses and cervical dysplasia in Alaska Native women. J Infect Dis. 1994 Apr; 169(4):792-800.
    View in: PubMed
    Score: 0.014
  79. Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013 Dec 21; 15:108.
    View in: PubMed
    Score: 0.014
  80. [Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary]. Clin Investig Arterioscler. 2014 Jan-Feb; 26(1):33-7.
    View in: PubMed
    Score: 0.014
  81. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014 Jan 01; 113(1):76-83.
    View in: PubMed
    Score: 0.014
  82. Mechanical versus bioprosthetic mitral valve replacement in patients <65 years old. J Thorac Cardiovasc Surg. 2014 Jan; 147(1):117-26.
    View in: PubMed
    Score: 0.014
  83. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013 Sep-Oct; 7(5):484-525.
    View in: PubMed
    Score: 0.014
  84. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24; 62(13):1154-62.
    View in: PubMed
    Score: 0.014
  85. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr; 19(2):327-36.
    View in: PubMed
    Score: 0.013
  86. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J. 2013 Apr; 34(13):962-71.
    View in: PubMed
    Score: 0.013
  87. Family history of schizophrenia and bipolar disorder as risk factors for autism. Arch Gen Psychiatry. 2012 Nov; 69(11):1099-1103.
    View in: PubMed
    Score: 0.013
  88. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. J Clin Lipidol. 2012 Nov-Dec; 6(6):534-44.
    View in: PubMed
    Score: 0.012
  89. Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women. Vasc Health Risk Manag. 2012; 8:31-8.
    View in: PubMed
    Score: 0.012
  90. Peripheral artery disease, biomarkers, and darapladib. Am Heart J. 2011 May; 161(5):972-8.
    View in: PubMed
    Score: 0.012
  91. Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease. J Clin Lipidol. 2011 May-Jun; 5(3):141-151.
    View in: PubMed
    Score: 0.012
  92. Drugs in development for management of lipoprotein disorders. J Clin Lipidol. 2011 Mar-Apr; 5(2):66-75.
    View in: PubMed
    Score: 0.012
  93. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol. 2011 Mar 15; 107(6):906-11.
    View in: PubMed
    Score: 0.012
  94. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16; 363(25):2406-15.
    View in: PubMed
    Score: 0.011
  95. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009 Dec; 7(6):601-10.
    View in: PubMed
    Score: 0.011
  96. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009 Jul 01; 104(1):74-81.
    View in: PubMed
    Score: 0.010
  97. The editor's roundtable: lipid management beyond statins-reducing residual cardiovascular risk. Am J Cardiol. 2008 Sep 01; 102(5):559-67.
    View in: PubMed
    Score: 0.010
  98. The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med. 2008 Oct; 5(10):621-35.
    View in: PubMed
    Score: 0.010
  99. Religious education and midlife observance are associated with dementia three decades later in Israeli men. J Clin Epidemiol. 2008 Nov; 61(11):1161-8.
    View in: PubMed
    Score: 0.010
  100. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother. 2008 May; 9(7):1237-48.
    View in: PubMed
    Score: 0.010
  101. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008 Apr 29; 51(17):1632-41.
    View in: PubMed
    Score: 0.010
  102. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008 Apr 15; 51(15):1512-24.
    View in: PubMed
    Score: 0.010
  103. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008 Apr; 31(4):811-22.
    View in: PubMed
    Score: 0.010
  104. Impaired diurnal blood pressure variation and all-cause mortality. Am J Hypertens. 2008 Jan; 21(1):92-7.
    View in: PubMed
    Score: 0.009
  105. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008 Mar; 197(1):12-24.
    View in: PubMed
    Score: 0.009
  106. Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med. 2007 May-Jun; 21(3):542-58.
    View in: PubMed
    Score: 0.009
  107. Relationship of traditional and nontraditional cardiovascular risk factors to coronary artery calcium in type 2 diabetes. Diabetes. 2007 Mar; 56(3):849-55.
    View in: PubMed
    Score: 0.009
  108. Advancing paternal age and autism. Arch Gen Psychiatry. 2006 Sep; 63(9):1026-32.
    View in: PubMed
    Score: 0.009
  109. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol. 2005 Nov; 46(5):594-9.
    View in: PubMed
    Score: 0.008
  110. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation. 2005 Aug 30; 112(9):1289-95.
    View in: PubMed
    Score: 0.008
  111. A genetic and epidemiologic study of cardiovascular disease in Alaska natives (GOCADAN): design and methods. Int J Circumpolar Health. 2005 Jun; 64(3):206-21.
    View in: PubMed
    Score: 0.008
  112. Treating dyslipidemia in high-risk patients: case reviews and discussion. Postgrad Med. 2004 Sep; 116(3 Suppl):21-8.
    View in: PubMed
    Score: 0.007
  113. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004; 65 Suppl 7:4-18; quiz 19-20.
    View in: PubMed
    Score: 0.007
  114. Cardiovascular disease among Alaska Natives: a review of the literature. Int J Circumpolar Health. 2003 Dec; 62(4):343-62.
    View in: PubMed
    Score: 0.007
  115. The role of cardiovascular risk factors in Alzheimer's disease. CNS Spectr. 2003 Nov; 8(11):824-33.
    View in: PubMed
    Score: 0.007
  116. Contemporary awareness and understanding of cholesterol as a risk factor: results of an American Heart Association national survey. Arch Intern Med. 2003 Jul 14; 163(13):1597-600.
    View in: PubMed
    Score: 0.007
  117. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003 Mar 10; 163(5):553-64.
    View in: PubMed
    Score: 0.007
  118. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol. 2003 Jan; 26(1):18-24.
    View in: PubMed
    Score: 0.007
  119. A cross-sectional study of lipids and ApoC levels in Alzheimer's patients with and without cardiovascular disease. J Gerontol A Biol Sci Med Sci. 2002 Nov; 57(11):M757-61.
    View in: PubMed
    Score: 0.007
  120. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002 Jul 03; 288(1):49-57.
    View in: PubMed
    Score: 0.006
  121. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry. 2002; 63 Suppl 9:25-9.
    View in: PubMed
    Score: 0.006
  122. Collaborative multidisciplinary workshop report: the role of epidemiology studies in determining a possible relationship between Chlamydia pneumoniae infection and atherothrombotic diseases. J Infect Dis. 2000 Jun; 181 Suppl 3:S430-1.
    View in: PubMed
    Score: 0.006
  123. Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal women. Am J Cardiol. 2000 Feb 15; 85(4):451-6.
    View in: PubMed
    Score: 0.005
  124. Low-density lipoprotein subclass distribution pattern and adiposity-associated dyslipidemia in postmenopausal women. J Am Coll Nutr. 2000 Feb; 19(1):23-30.
    View in: PubMed
    Score: 0.005
  125. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry. 1999 Jan 01; 45(1):32-40.
    View in: PubMed
    Score: 0.005
  126. Fiber intake and risk of developing non-insulin-dependent diabetes mellitus. JAMA. 1997 Jun 11; 277(22):1761; author reply 1762.
    View in: PubMed
    Score: 0.005
  127. Risk factors for nasopharyngeal carriage of resistant Streptococcus pneumoniae and detection of a multiply resistant clone among children living in the Yukon-Kuskokwim Delta region of Alaska. Pediatr Infect Dis J. 1996 Nov; 15(11):986-92.
    View in: PubMed
    Score: 0.004
  128. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996 Aug 15; 78(4):409-14.
    View in: PubMed
    Score: 0.004
  129. Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Res. 1991 Sep; 38(3):285-92.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.